Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APLS Apellis Pharmaceuticals Inc.

Post-Mkt 04-13 19:13:49 EDT

40.84

+0.05

+0.12%

盘后40.80

-0.04-0.09%

18:20 EDT

High40.87	Low40.70	Vol5.83M
Open40.73	D1 Closing40.79	Amplitude0.42%
Mkt Cap5.22B	Tradable Cap3.19B	Total Shares127.83M
T/O237.80M	T/O Rate7.46%	Tradable Shares78.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":40.84,"timestamp":1776110400000,"preClose":40.79,"halted":0,"volume":5828232,"hourTrading":{"tag":"盘后","latestPrice":40.8016,"preClose":40.84,"latestTime":"18:20 EDT","volume":6016,"amount":245692.05632,"timestamp":1776118829716,"change":-0.0384,"changeRate":-0.00094,"amplitude":0.001224},"delay":0,"changeRate":0.0012257906349596535,"floatShares":78119932,"shares":127829909,"eps":0.172407,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"04-13 19:13:49 EDT","open":40.73,"high":40.87,"low":40.7,"amount":237797618.064984,"amplitude":0.004168,"askPrice":40.9,"askSize":50,"bidPrice":40.8,"bidSize":127,"shortable":3,"etf":0,"ttmEps":0.172407,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776124800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":40.79,"preHourTrading":{"tag":"盘前","latestPrice":40.72,"preClose":40.79,"latestTime":"09:29 EDT","volume":5440,"amount":221561.32095999998,"timestamp":1776086999999,"change":-0.07,"changeRate":-0.001716,"amplitude":0.003187},"postHourTrading":{"tag":"盘后","latestPrice":40.8016,"preClose":40.84,"latestTime":"18:20 EDT","volume":6016,"amount":245692.05632,"timestamp":1776118829716,"change":-0.0384,"changeRate":-0.00094,"amplitude":0.001224},"volumeRatio":1.012829,"impliedVol":0.0525,"impliedVolPercentile":0.012},"requestUrl":"/m/hq/s/APLS","defaultTab":"news","newsList":[{"id":"2627590784","title":"BUZZ-Citi, Truist trim PT on Biogen ahead of Q1 earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2627590784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627590784?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:36","pubTimestamp":1776090969,"startTime":"0","endTime":"0","summary":"BUZZ-Citi, Truist trim PT on Biogen ahead of Q1 earnings** Citi maintains a \"neutral\" rating on Biogen BIIB.O shares and cuts price target to $190 from $215** Truist Securities maintains \"hold\" rating on the stock and cuts PT to $189 from $193** Truist says its lower target mainly reflects the expected financial impact of BIIB's $5.6 billion Apellis APLS.O deal, including forecasts for APLS' approved drugs Syfovre and Empaveli** \"Turnaround still in motion, but execution remains the proof point\" - Citi ** Says BIIB's Alzheimer's drug Leqembi remains the main growth story, but sales will likely rise only gradually even after U.S. FDA clears a self-injection version of the drug in May** Adds that uptake will be slow, given brain scans are likely what doctors prefer for amyloid confirmation** Newer drugs such as Skyclarys and Zurzuvae should support growth while older drugs remain under pressure - Citi** BIIB shares up 0.9% at $174.54** Including session's move, BIIB down 0.8% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4N40W16H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU2125154935.USD","LU0052756011.USD","LU0162691827.USD","IE00B894F039.SGD","LU0980610538.SGD","LU0130517989.USD","LU0109394709.USD","LU1244550221.USD","LU0130102774.USD","LU1244550577.SGD","LU2360032135.SGD","LU0128525689.USD","BK4505","LU2417539215.USD","IE00B19Z9P08.USD","IE00BSNM7G36.USD","BK4566","LU0889565916.HKD","LU1201861249.SGD","LU0098860793.USD","LU0072461881.USD","LU1093756168.USD","LU1791807156.HKD","LU0314106906.USD","BK4585","LU1668664300.SGD","APLS","LU0320765992.SGD","BK4207","LU0106831901.USD","LU2456880835.USD","LU0234570918.USD","LU1162221912.USD","LU0648001328.SGD","LU1244550494.USD","BK4559","LU0170899867.USD","BK4504","BK4139","BK4534","LU0477156953.USD","BK4533","BIIB","LU1267930227.SGD","LU0320765646.SGD","LU2236285917.USD","BK4532","LU2125154778.USD","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953097","title":"RBC Adjusts Price Target on Apellis Pharmaceuticals to $41 From $21, Maintains Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953097","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953097?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:05","pubTimestamp":1775567107,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $39.94, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BK4588","LU1093756325.SGD","APLS","BK4139","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625293454","title":"Apellis Pharmaceuticals Inc : RBC Raises Target Price to $41 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2625293454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625293454?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:33","pubTimestamp":1775557981,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q0OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","LU1093756325.SGD","BK4139","BK4505","APLS","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625933307","title":"U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2625933307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625933307?lang=en_us&edition=fundamental","pubTime":"2026-04-07 16:04","pubTimestamp":1775549040,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO April 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TXG","AN","AKAM","BX","AMZU","BAC","APLE","AMZD","AXP","AMZN","BRBR","CELH","CSR","AJG","BIIB","CNC","ASB","BKNG","BWIN","AX","AU","ARRY","BOW","ARCB","BANC","CVNX","ANET","BKR","AMGN","ABG","BKNU","CBOE","COF","CVNA","BKU","CVNY","AA","BIO","AMP","CNCG","BOH","SAM","AMZY","AMZP","AEIS","APLS","CELT","BOKF","OZK","AMZW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625675079","title":"Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get","url":"https://stock-news.laohu8.com/highlight/detail?id=2625675079","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625675079?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:40","pubTimestamp":1775472000,"startTime":"0","endTime":"0","summary":"Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/06/Candlestick-Graph-Chart-Of-Stock-And-For.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/06/Candlestick-Graph-Chart-Of-Stock-And-For.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/26/04/51653630/apellis-stock-soars-after-biogen-deal-momentum-score-surges-heres-what-shareholders-get","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/26/04/51653630/apellis-stock-soars-after-biogen-deal-momentum-score-surges-heres-what-shareholders-get","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1093756168.USD","APLS","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0234570918.USD","LU0320765992.SGD","LU1093756325.SGD","BK4588","BK4139","IE00B19Z9P08.USD","BIIB","BK4585","BK4532","BK4505","SLNO","LU0889565916.HKD","LU0109394709.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624669875","title":"The Trader: Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs. -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624669875?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:30","pubTimestamp":1775266200,"startTime":"0","endTime":"0","summary":"Big Pharma companies are constantly searching for the next hot new drugs -- and it's often a lot easier to buy them than develop them. That's great news for biotech investors. Merger activity is starting to heat up again in the sector.There were three notable deals in March alone. Biogen just announced a deal to buy Apellis Pharmaceuticals, a developer of immunological and rare-disease medications, for $5.6 billion, a takeover premium of nearly 140%. Mounjaro owner Eli Lilly is buying sleep-drug maker Centessa Pharmaceuticals for $7.8 billion. And Merck said it would buy Terns Pharmaceuticals, which is working on a drug to treat leukemia, for $6.7 billion.Mergers won't be the only catalyst for biotechs. Analysts at Cantor Fitzgerald pointed out in a report in March that they expect about 80% of the companies in the State Street SPDR S&P Biotech ETF will have approved drugs by the third quarter of next year. This, according to Cantor, suggests the industry is \"still early in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","KALV","BK4539","IE00B2B36J28.USD","BK4588","STT","BK4135","BK4505","IE0002141913.USD","IE00B3QW5Z07.USD","IE0009355771.USD","LU1983260115.SGD","IE00BFTCPJ56.SGD","LU1883839398.USD","LU1894683348.USD","ARGX","LU1093756325.SGD","CNTA","TERN","IE00BGHQF748.EUR","LU0061475181.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU1093756168.USD","BK4585","LU0889565916.HKD","BK4535","LU2324357040.USD","BK4007","LU0109394709.USD","IE00BJJMRZ35.SGD","LU1894683264.USD","APLS","BK4139","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624662737","title":"Build More New Houses -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2624662737","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624662737?lang=en_us&edition=fundamental","pubTime":"2026-04-04 06:10","pubTimestamp":1775254200,"startTime":"0","endTime":"0","summary":"The Census Bureau's latest population estimates illustrate how housing supply supports -- or stunts -- growth. More than two-thirds of metro areas in June 2025 had fewer listings than in 2019, before the pandemic supercharged housing and rising mortgage rates pushed buyers and sellers to the sidelines. But of the 10 fastest-growing metropolitan areas in 2025, nine had more homes for sale than before the pandemic, a Barron's analysis of Realtor.com and government data suggest.The central Florida metro of Ocala had the biggest population percentage gain in the U.S. last year, per Census estimates, followed by Myrtle Beach and Spartanburg, S.C. Listings in No. 6 Huntsville, Ala., were 78% higher than in 2019. \"What [the data] does tell us is that there is still demand for housing in more affordable parts of the country,\" says Eric Finnigan, vice president of demographics research at John Burns Research and Consulting.Unilever announced a $44.8 billion deal with McCormick to merge food ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0215105999.USD","LU1935042215.USD","LU1267930730.SGD","LU1803068979.SGD","LU1116320901.HKD","LU2896262040.SGD","HK0000304805.HKD","LU2456880835.USD","LU0109392836.USD","IE0001KFT4U8.USD","LU1839511570.USD","SG9999002224.SGD","IE00BDCRKT87.USD","LU1267930227.SGD","BK4599","LU0348723411.USD","IE0000B7K699.USD","LU1917777945.USD","LU0265550359.USD","LU1868837300.USD","LU2264538146.SGD","LU0203347892.USD","LU0187121727.USD","LU0889566641.SGD","LU1153585028.USD","IE000BZT7R73.USD","LU1823568750.SGD","LU0342679015.USD","IE00BJJMRZ35.SGD","LU0784385170.HKD","LU2112291526.USD","LU0238689110.USD","LU1551013425.SGD","LU0788109477.HKD","LU2237443465.HKD","GOOY","LU0787776722.HKD","LU2746668974.SGD","LU0289739699.SGD","LU0965508806.USD","LU0949170426.SGD","BK4532","LU1064131342.USD","LU1934455863.HKD","LU1201861249.SGD","LU0109391861.USD","LU2125909247.SGD","IE000SO60NU8.SGD","LU1868836757.USD","LU0130517989.USD","SG9999014898.SGD","LU2168564495.EUR","LU1645745479.HKD","LU1880398554.USD","LU0528227936.USD","LU1267930813.SGD","LU2023250843.SGD","LU1803068623.USD","LU0256863902.USD","LU1935043023.USD","LU2764263039.SGD","IE00BK4W5L77.USD","LU0432979614.USD","IE00B19Z9Z06.USD","LU2756315318.SGD","IE00B775H168.HKD","LU1983299246.USD","IE00BK4W5M84.HKD","LU0316494557.USD","LU0130103400.USD","LU0477156953.USD","LU2362540622.SGD","LU1496350171.SGD","LU0708994859.HKD","LU0466842654.USD","IE00B5TLWC47.USD","LU0868494708.USD","BK4587","LU1674673428.USD","LU1674673691.USD","LU0124676726.USD","LU2089283258.USD","LU2360032135.SGD","LU0077335932.USD","IE00B3S45H60.SGD","LU0689472784.USD","BK4581","LU2250418816.HKD","LU0823421416.USD","LU0267386448.USD","IE0034235188.USD","BK4548","SGXZ81514606.USD","LU1023059063.AUD","LU2404859741.USD","LU0106261372.USD","LU1059921491.USD","LU1778281490.HKD","LU2403377893.USD","LU2433249047.HKD","LU2324357040.USD","LLYZ","GB00B4QBRK32.GBP","LU1951198990.SGD","LU0354030438.USD","LU0882574055.USD","LU0107464264.USD","LU1069347547.HKD","IE00B5949003.HKD","LU2860962120.EUR","ELIS","LU0154236417.USD","LU2265009873.SGD","LU2361044949.HKD","IE00BQXX3D17.EUR","IE0002141913.USD","BK4576","HK0000304797.USD","IE00B775SV38.USD","LU0302445910.USD","BK4592","LU1623119135.USD","LU0122379950.USD","IE00B19Z8X17.USD","LU1267930490.SGD","LU1934455194.USD","LU0823434740.USD","LU1244550577.SGD","IE00BFSS7M15.SGD","LU1121112475.USD","LU1061106388.HKD","LU1951200564.SGD","LU2063271972.USD","LU2404859667.USD","IE0009355771.USD","LU2471134796.USD","IE00BN29S564.USD","LU0648000940.SGD","LU0553294199.USD","LU1400636657.SGD","LU2077746001.SGD","LU0158827948.USD","GOOGL","LU1989764748.USD","LU2471134952.CNY","IE00BJJMRX11.SGD","LU0320765489.SGD","IE00B4R5TH58.HKD","LU1894683264.USD","IE00B19Z9P08.USD","BK4585","LU0965509101.SGD","BK4503","LU0208291251.USD","LU0157215616.USD","IE00BLSP4239.USD","LU1066051498.USD","LU0724617625.USD","LU1548497426.USD","LU0385154629.USD","LU0456855351.SGD","LU2106854487.HKD","LU2360106780.USD","LU0068578508.USD","LU0210528500.USD","LU1489326972.SGD","LU2191332357.HKD","LU0965509010.AUD","LU1003077747.HKD","LU1035773651.USD","LU0211327993.USD","BK4612","IE00BMPRXN33.USD","BIIB","BK4533","LU0158827781.USD","LU1430594728.SGD","LU0345774631.USD","NKE","IE00BMPRXR70.SGD","LU2463028550.USD","LU0683600562.USD","LU0820562030.AUD","LU1303367103.USD","LU2326559502.SGD","LU0672654240.SGD","LU2362541513.USD","LU2552382215.SGD","LU0823434583.USD","LU0708995401.HKD","LU2471134879.HKD","APLS","LU2125154778.USD","LU1316542783.SGD","LU0048584097.USD","LU1232071149.USD","IE00BSNM7G36.USD","LU1974910355.USD","LU2097344357.USD","LU2360106947.USD","LU0061474705.USD","LU2028103732.USD","LU1323610961.USD","GB00BDT5M118.USD","LU0957791311.USD","LU0211326839.USD","IE00BJJMRY28.SGD","LU1814569148.SGD","LU2213496289.HKD","LU0738911758.USD","SG9999000418.SGD","BK4566","IE00BJTD4V19.USD","LU2430703251.USD","IE00BHPRN162.USD","LU1066051225.USD","IE00B894F039.SGD","GOOP","LU0265550946.USD","LU0130518102.USD","LU0985320562.USD","LU0128525689.USD","LU0820561818.USD","LU0029864427.USD","LU0094547139.USD","LU1043141123.HKD","LU2430703178.SGD","LU0889565916.HKD","BK4507","LU1066053197.SGD","IE00BFMHRM44.USD","LU0114720955.EUR","LU0138981039.USD","LU2461242641.AUD","LU1642822529.SGD","LU1366192091.USD","GOOX","LU2237438978.USD","LU2471134523.USD","LU0128525929.USD","LU2168564149.EUR","LU2271345857.HKD","LU0234570918.USD","LU2750360997.AUD","LU1935042991.SGD","LU2750360641.GBP","LU2764263203.CNY","BK4553","IE00B4JS1V06.HKD","IE00B1BXHZ80.USD","LU2468319806.SGD","LU0211326755.USD","LU0742534661.SGD","LU0417517546.SGD","LU1244550221.USD","LU1119994496.HKD","LU0109394709.USD","LU1093756325.SGD","LU2247934214.USD","GGLS","LU0130102774.USD","IE00BKVL7J92.USD","IE00B19Z9505.USD","LU0345769128.USD","LU0353189763.USD","LU0314106906.USD","LU2023250504.SGD","LU0433182093.SGD","IE00BJTD4N35.SGD","GGLL","BK4007","LU0345774391.USD","SGXZ57979304.SGD","LU0943347566.SGD","LU0823416689.USD","UL","SG9999017495.SGD","LU2552382058.USD","LU2381873111.SGD","LU2764262908.HKD","LU0786609619.USD","LU1691799644.USD","IE0034235295.USD","LU0426412945.USD","LU2720916845.USD","LU1035775433.USD","IE0034235303.USD","LU2023250330.USD","LU0689626769.HKD","LU1989764664.SGD","LU2242649171.HKD","LU0056508442.USD","LU2211815571.USD","LU0203345920.USD","LU1244550494.USD","BK4077","LU1670756490.USD","LU2237443549.SGD","LU0661504455.SGD","LU1093756168.USD","LU0690374961.EUR","IE00B19Z3581.USD","LU1720051017.SGD","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0225283273.USD","SG9999014914.USD","LU1196500208.SGD","LU1074936037.SGD","LU0072462426.USD","LU1923623000.USD","LU1791710582.SGD","LU0878866978.SGD","SG9999014880.SGD","USJW.SI","LU2168563687.JPY","LU0310799852.SGD","SG9999013999.USD","IE00B2B36J28.USD","LU1551013342.USD","IE00BJLML261.HKD","BK4598","LU1235294995.USD","LU2462157665.USD","LU0820561909.HKD","LU1815336760.USD","LU0276348264.USD","LU1037948897.HKD","LU2362541273.HKD","LU0175139822.USD","LU0965509283.SGD","SG9999018865.SGD","IE00BQXX3C00.GBP","LU0211331839.USD","LU0310800379.SGD","SG9999015945.SGD","LU1400636574.HKD","LU0211328371.USD","LU0320765059.SGD","LU1116320737.USD","LU0345770993.USD","LU2505996681.GBP","LU1127390331.HKD","LU2065170008.USD","LU2357305700.SGD","LU0345768740.USD","LU0058720904.USD","LU1506573853.SGD","LU0314104364.USD","LU0011850046.USD","IE0004086264.USD","LU0070217475.USD","IE0009356076.USD","LU0251131958.USD","LU0784385840.USD","IE00BDRTCR15.USD","ELIL","LU0345770308.USD","LU1032955483.USD","LU2244417387.USD","LU0053666078.USD","LU2065171402.SGD","LU0052756011.USD","BK4588","LU0980610538.SGD","IE00BQXX3F31.USD","LU0079474960.USD","LU1585245621.USD","LU1261432733.SGD","LU1435385759.SGD","LU0256863811.USD","LU1804176565.USD","LU0345769631.USD","SG9999001176.USD","GOOW","BK4527","LU0203201768.USD","LU1914381329.SGD","LU2237443978.SGD","IE00BKPKM429.USD","LU1496350502.SGD","IE00BFSS8Q28.SGD","LU2491050154.USD","LU1400636491.USD","LU2361045086.USD","LU0471298694.HKD","LU0096364046.USD","LU0210536198.USD","LU2065171311.SGD","LU2491049909.HKD","LU2552382132.HKD","LU1989771016.USD","LU2092627202.USD","LU0149725797.USD","MKC","LU1201861165.SGD","LLYX","LU0210533765.USD","LU0354030511.USD","LU1934455277.USD","LU2417539215.USD","BK4139","IE00BFXG0V08.USD","LU2065169927.USD","IE00B19Z3B42.SGD","LU0964807845.USD","LU0308772762.SGD","LU0861579265.USD","LU1084165304.USD","LU0048573561.USD","LU0942090050.USD","LU2108987350.USD","LU2746668461.USD","IE00BLSP4452.SGD","IE000MB6IJN5.SGD","IE00BYQQ9H92.USD","LU2361044865.SGD","LU2286300806.USD","LU1633808545.USD","LU0642271901.SGD","LU1267930573.SGD","BK4525","LU2420271590.USD","IE00BMPRXQ63.HKD","LU0976567544.SGD","SG9999002232.USD","BK4574","LU1880398471.USD","BK4516","BK4538","LU0444973449.USD","IE00B19Z8W00.USD","LU1935042488.USD","SGXZ99366536.SGD","LU0640476718.USD","LU2089984988.USD","LU0353189680.USD","SG9999015978.USD","LU0823421333.USD","IE00BJT1NW94.SGD","LU0170899867.USD","LU0444971666.USD","LU2237443895.HKD","LU1571399168.USD","LU1868837136.USD","IE000M9KFDE8.USD","LU0868494617.USD","BK4579","LU2097829019.USD","LU0070302665.USD","LU2125154935.USD","LU1894683348.USD","IE000F7OJYX1.SGD","LU2487616109.SGD","BK4550","LU0985489474.SGD","LU1046421795.USD","LU1699723380.USD","LU2602419157.SGD","LU2543165471.USD","LU0006306889.USD","LU2054465674.USD","LU2087625088.SGD","LU2236285917.USD","LU0690374615.EUR","LU2491050071.SGD","LU2089284900.SGD","IE00BBT3K403.USD","LU0320765992.SGD","LU1202635105.USD","LU1718418525.SGD","LU1301847155.USD","LU0234572021.USD","LU0792757196.USD","LU1429558221.USD","LU1868836914.USD","BK4505","LU0323591593.USD","SG9999018857.SGD","LU0719512351.SGD","LU2505996509.AUD","LU2275660780.HKD","LU2097344431.USD","LU2168564065.EUR","IE00BZ1G4Q59.USD","LU1852331112.SGD","LU0477156797.USD","LU1280957306.USD","LU2430703095.HKD","LU2087621335.USD","LU1989772840.SGD","LU0784384876.USD","IE000WAW04H5.SGD","LU1815333072.USD","LU0289941410.SGD","LU1057294990.SGD","IE00BN8TJ469.HKD","LU1066051811.HKD","LU0127658192.USD","LU0889565833.HKD","LU2458330169.SGD","LU0266013472.USD","BK4573","LU2237443382.USD","LU2098885051.SGD","IE0005OL40V9.USD","LU1629891620.HKD","LU2092937148.SGD","LU1988902786.USD","LU1043141396.HKD","LU1712237335.SGD","LU1989772923.USD","LU0198837287.USD","LU1221951129.SGD","GOU","LLII","LU0310800965.SGD","LU0496365809.HKD","LU0545039389.USD","LU0061474960.USD","IE00B7SZLL34.SGD","LU2458330243.SGD","LU0471298777.SGD","SG9999001077.SGD","LU0784383803.USD","LU1791710400.SGD","LU2023251221.USD","SG9999015952.SGD","LU0080751232.USD","LU1923622614.USD","LU0312595415.SGD","LU0476273544.USD","BK4543","LU1291159041.SGD","SG9999015986.USD","IE00BWXC8680.SGD","IE0004091025.USD","SGXZ31699556.SGD","IE0002270589.USD","SGXZ51526630.SGD","LU2592432038.USD","IE00BZ199S13.USD","LU0251142724.SGD","LU0251132253.USD","LU0994945656.USD","IE00BKDWB100.SGD","LLY","BK4561","LU0082616367.USD","SG9999014906.USD","LU0097036916.USD","LU2756315664.SGD","LU0882574139.USD","LU0345768153.USD","LU1670627923.USD","BK4534","LU2111349929.HKD","LU0957808578.USD","LU1720051108.HKD","LU0949170772.SGD","SG9999001176.SGD","LU2237443622.USD","IE00B1XK9C88.USD","LU0203202063.USD","LU1145028129.USD","IE0004445239.USD","LU1037948541.HKD","IE00B7KXQ091.USD","BK4602","IE0004445015.USD","LU1935043536.SGD","LU1366333091.USD","LU1868836591.USD","GB00B4LPDJ14.GBP","IE00BYXW3230.USD","LU0426417589.USD","LU0494093205.USD","LU2242650005.HKD","BK4514","LU1069344957.HKD","LU1670628061.USD","BK4554","LU0096362180.USD","LU2125909593.SGD","LU2168564222.USD","LU0289960550.SGD","LU0557290698.USD","LU1221951046.USD","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624508565","title":"Apellis Pharmaceuticals Inc : Mizuho Raises Target Price to $41 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2624508565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624508565?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:37","pubTimestamp":1775126251,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","LU1093756168.USD","LU1093756325.SGD","BK4139","BK4505","APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624571205","title":"Apellis downgraded to Neutral from Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2624571205","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624571205?lang=en_us&edition=fundamental","pubTime":"2026-04-02 16:31","pubTimestamp":1775118661,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Adam Walsh downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, up from $31, following Biogen’s (BIIB) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","IE00B19Z9Z06.USD","LU1093756325.SGD","BK4139","IE00B894F039.SGD","BK4505","BK4532","BK4588","LU0320765992.SGD","LU0889565916.HKD","LU1093756168.USD","IE00B19Z9P08.USD","LU0109394709.USD","LU0234570918.USD","BIIB","APLS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624575278","title":"U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2624575278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624575278?lang=en_us&edition=fundamental","pubTime":"2026-04-02 15:21","pubTimestamp":1775114493,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United TherapeuticsApril 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL4N40L0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DIN","BOH","ALAB","CSL","BYND","STZ","AZYY","DASX","GOU","COP","CVX","BJRI","AMZN","CVI","GPN","LNG","FBIN","CQP","FBK","BARK","XOM","BHVN","GD","GOOP","GOOGL","USAW.SI","CACI","GOOY","CFG","GENK","CW","CEG","ANRO","DASH","AROC","CTRE","BETA","CAG","BAH","DK","GE","GGLL","XOMZ","BAC","DCO","GOOW","GOOX","APLS","BA","CAVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624242527","title":"Apellis Pharmaceuticals Cut to Neutral From Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2624242527","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624242527?lang=en_us&edition=fundamental","pubTime":"2026-04-02 13:15","pubTimestamp":1775106900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 01:15 ET (05:15 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4588","APLS","BK4139","BK4505","BK4585","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624751179","title":"Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624751179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624751179?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:00","pubTimestamp":1775052020,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (AP...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rani-therapeutics-holdings-rani-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rani-therapeutics-holdings-rani-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4007","HCSG","BK4137","LU0029874061.USD","XLV","XBI","BK4581","BK4505","LU1093756168.USD","RANI","APLS","LU1093756325.SGD","LU0128526141.USD","BK4588","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590059","title":"BUZZ-Street View: Biogen's $5.6 billion Apellis bet a strategic fit","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590059","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590059?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:31","pubTimestamp":1775043094,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Biogen's $5.6 billion Apellis bet a strategic fit ** Biogen BIIB.O agreed to buy Apellis Pharmaceuticals APLS.O for about $5.6 billion, adding a promising kidney disease drug to broaden its rare-disease portfolio amid efforts to diversify beyond its slowing multiple sclerosis franchise.** At least two analysts raised PT on BiogenPRESSING NEED** Needham  says the acquisition has strong strategic value for Biogen's key late-stage kidney drug felzartamab, though the deal economics longer-term may be uncertain** Citi  says there was an \"increasingly pressing need\" for business development deals before its late-stage pipeline of drugs mature** Brokerage says the pressure on Biogen shares after the deal was due to \"the lack of an inflection point investors had hoped for\"  ** Oppenheimer  says decision to acquire APLS is consistent with BIIB's previously articulated business development strategy ** Brokerage says the addition of APLS's approved drug Empaveli provides \"an est","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL4N40K0YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","LU0109394709.USD","BK4588","BK4585","BIIB","BK4533","LU1093756168.USD","LU0320765992.SGD","BK4532","LU0889565916.HKD","LU1093756325.SGD","IE00B19Z9P08.USD","BK4139","LU0234570918.USD","BK4505","APLS","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624129590","title":"Wedbush Raises Price Target on Apellis Pharmaceuticals to $41 From $18, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624129590","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624129590?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:24","pubTimestamp":1775042658,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $36.94, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APLS","BK4139","LU1093756325.SGD","LU1093756168.USD","BK4585","BK4588","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624359063","title":"Apellis Pharmaceuticals Inc : Raymond James Cuts to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2624359063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624359063?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:18","pubTimestamp":1775042313,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4588","LU1093756325.SGD","BK4585","BK4139","LU1093756168.USD","APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624597170","title":"Apellis Pharmaceuticals Inc : William Blair Cuts to Market Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624597170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624597170?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:01","pubTimestamp":1775041295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756325.SGD","LU1093756168.USD","BK4139","BK4585","APLS","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624075594","title":"Apellis downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2624075594","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624075594?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:12","pubTimestamp":1775038340,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, down from $48, to reflect the pendin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","LU1093756325.SGD","BK4585","APLS","BK4139","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591042","title":"Deals of the day-Mergers and acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591042","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624591042?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:00","pubTimestamp":1775037645,"startTime":"0","endTime":"0","summary":"Deals of the day-Mergers and acquisitionsApril 1 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Wednesday:** The field of suitors for British aerospac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL6N40K0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023251221.USD","GB00B4LPDJ14.GBP","ULVR.UK","LU1509826696.USD","LU1814569148.SGD","03165","IE00BVYPNT70.USD","MKC","LU0550127509.SGD","LU0878866978.SGD","LU1400636574.HKD","LU2091194634.USD","IE00BVYPNV92.GBP","LU2242652126.USD","LU0742537680.HKD","LU0128525689.USD","SNR.UK","BK4588","BIIB","BK4597","IE00B19Z9Z06.USD","LU2089283258.USD","LU2404859667.USD","IE00BVYPNW00.USD","BAES.UK","LU1015430645.USD","LU1302929846.USD","BK5127","LU3187612489.SGD","BK4139","APLS","BK5131","LU1093756168.USD","LU1920062954.HKD","LU0742534661.SGD","LU1019632923.USD","LU0048573561.USD","LU0997586606.USD","LU1023061473.USD","IE0034235071.USD","LU1989763690.USD","LU1119994140.HKD","LU2491049909.HKD","LU0345770308.USD","LU0068578508.USD","LU0251131958.USD","LU2211817866.USD","LU0772969993.USD","LU1481599808.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593841","title":"U.S. RESEARCH ROUNDUP-Asana, PPG Industries, Verisign","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624593841?lang=en_us&edition=fundamental","pubTime":"2026-04-01 15:57","pubTimestamp":1775030227,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Asana, PPG Industries, Verisign April 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Asana, PPG","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL8N40K0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","CUBI","BXP","COLD","BKNU","BANC","CRWD","ATI","BWXT","DDOG","ASAN","CEGX","ALGT","CCK","KO","CBRE","CVX","MMM","O","CTRI","SG9999015358.SGD","BAH","BK","EMR","STZ","BPH","ALK","BALL","BIIB","EOG","LU0130102774.USD","ABNY","XRN","AVY","DOGD","ATMU","BKNG","AAMI","APLS","BP","CEG","LU1721429741.USD","CRWL","PLAY","BLK","ABNB","CACI","CARR","COLB","ABNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624387561","title":"Apellis Pharmaceuticals Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $41 From $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2624387561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624387561?lang=en_us&edition=fundamental","pubTime":"2026-04-01 13:10","pubTimestamp":1775020231,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K09C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4585","LU1093756168.USD","LU1093756325.SGD","APLS","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":1.1047},{"period":"3month","weight":0.4941},{"period":"6month","weight":0.6238},{"period":"1year","weight":1.1708},{"period":"ytd","weight":0.6238}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.03559},{"month":2,"riseRate":0.555556,"avgChangeRate":0.020983},{"month":3,"riseRate":0.555556,"avgChangeRate":0.121941},{"month":4,"riseRate":0.666667,"avgChangeRate":0.036896},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.130311}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}